Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Travere Therapeutics, Inc. < Previous 1 2 Next > Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference July 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 11, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 15, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress May 09, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present at Upcoming Investor Conferences May 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports First Quarter 2024 Financial Results May 06, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Report First Quarter 2024 Financial Results April 29, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy April 24, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers ASX:CSL CSLLY TVTX Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International April 04, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association April 03, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 13, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN) March 11, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present at Upcoming Investor Conferences February 26, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy February 23, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers ASX:CSL CSLLY TVTX Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results February 15, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results February 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference February 01, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations January 25, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Provides Corporate Update and 2024 Outlook January 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU) December 14, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS December 04, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference November 21, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports Third Quarter 2023 Financial Results November 07, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023 November 03, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Report Third Quarter 2023 Financial Results October 24, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 October 13, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 11, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023) September 26, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan September 21, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Tickers TVTX < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.